Introduction to CALML6 (G163688)

Target Name: CALML6

NCBI ID: G163688

CALML6

Introduction to CALML6

CALML6 (Calmodulin-like protein 6) has emerged as a promising drug target and biomarker in recent years. This article aims to provide a comprehensive understanding of CALML6, its role in various biological processes, and its potential implications in drug development and disease diagnostics.

The Discovery of CALML6:

CALML6 is a member of the calmodulin superfamily, discovered in 2003 by researchers studying the human calmodulin-binding proteins. Initially, CALML6 was classified as a calmodulin-like protein due to its structural similarities to calmodulin, a highly conserved calcium-binding protein involved in intracellular signaling pathways.

The Structure and Function of CALML6:

CALML6 is a small protein consisting of 148 amino acids, organized into two globular domains with four calcium-binding EF-hand motifs. These motifs enable CALML6 to undergo conformational changes upon calcium binding, thereby regulating its interaction with various target proteins.

While the exact function of CALML6 is still being elucidated, studies suggest its involvement in calcium-dependent signal transduction cascades. CALML6 is predominantly found in the cytoplasm and nucleus, where it interacts with different proteins to modulate their activities.

The Role of CALML6 in Biological Processes:

CALML6 has been identified to play a crucial role in several key physiological processes. One of its well-established functions is its participation in cell proliferation and differentiation. Through its association with specific proteins, CALML6 influences gene expression, cell cycle progression, and cellular responses to growth factors.

Moreover, CALML6 has been implicated in neuronal development and synaptic plasticity. It is known to interact with proteins involved in neurite outgrowth and dendritic spine formation, suggesting its involvement in the formation and maintenance of neuronal connections.

Furthermore, CALML6 has been linked to cancer progression. Elevated CALML6 expression has been observed in various tumors, including breast, lung, and ovarian cancers. Studies have shown that CALML6 promotes cancer cell survival, migration, and invasion, making it an attractive target for therapeutic interventions.

The Potential of CALML6 as a Drug Target:

Understanding the molecular mechanisms of CALML6's involvement in disease pathogenesis has led to the exploration of CALML6 as a potential drug target. By modulating CALML6 activity or its interaction with key protein partners, it might be possible to develop targeted therapies for various diseases, including cancer.

Researchers have begun developing small molecules and peptides that can selectively bind to CALML6, either inhibiting or enhancing its functions. These molecules can potentially disrupt the aberrant signaling pathways associated with diseases and restore normal cellular processes.

The Challenges and Future Directions:

While the potential of CALML6 as a drug target is promising, several challenges remain. One major hurdle is developing specific modulators that target CALML6 without affecting the closely related calmodulin protein. Discrimination between these two proteins is crucial for ensuring the efficacy and safety of CALML6-targeted therapies.

Another challenge lies in identifying the downstream targets of CALML6 and understanding the consequences of its modulation. Elucidating the molecular pathways regulated by CALML6 will aid in the development of more precise therapeutic strategies.

Moreover, further research is needed to explore the role of CALML6 as a potential biomarker for diseases. Detecting CALML6 expression levels might provide valuable diagnostic information about certain cancers or neurodevelopmental disorders, allowing for early detection and personalized treatments.

Conclusion:

CALML6 has emerged as a fascinating drug target and biomarker due to its involvement in diverse biological processes and disease pathogenesis. Ongoing research in this field holds great promise for the development of novel therapeutic interventions and diagnostic approaches. With further understanding of CALML6's function and its role in diseases, we may unlock new opportunities for personalized medicine and improved patient outcomes.

Protein Name: Calmodulin Like 6

The "CALML6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CALML6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets